Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02730793 · ClinicalTrials.gov registry record · Phase 2
Aztreonam Aerosol to Treat Cystic Fibrosis Nasal Disease
A Phase 2 study, sponsored by Virginia Commonwealth University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT02730793: Clinical Trial Phase 2 study, sponsored by Virginia Commonwealth University.
NCT02730793 is a Phase 2 study that was terminated before completion, run by Virginia Commonwealth University. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02730793, a Phase 2 study, was terminated before completion, sponsored by Virginia Commonwealth University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study is designed as a masked, two center, randomized, placebo-controlled pilot study to evaluate the safety and efficacy of nasal and oral inhalation of 75 mg aztreonam in subjects with CF and lung infection due to PA. The study will involve two sites: Virginia Commonwealth University Medical Center (VCU) and Eastern Virginia Medical School (EVMS). Potential subjects will be identified in each site's CF clinic.
Primary Outcome
Protocol-Defined Pulmonary Exacerbation includes events that are characterized by change or worsening pulmonary symptoms (increased cough, increased sputum production and chest congestion, decreased appetite and exercise tolerance), loss of weight, and lung function decline that prompt initation of antibiotic therapy. Protocol-defined exacerbations in subjects that warrant treatment with IV antibiotics will be determined from the medical record during the course of this study.
Interventions
- DRUG Nasal Placebo
- DRUG Oral Aztreonam
- DRUG Nasal Aztreonam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-01 |
| Est. Completion | 2019-09-19 |
| Phase | Phase 2 |
Why NCT02730793 stopped before completion
NCT02730793 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 3 interventions - of which Nasal Placebo is the first listed.
NCT02730793 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02730793 about?
NCT02730793 is a clinical study titled "Aztreonam Aerosol to Treat Cystic Fibrosis Nasal Disease". This study is designed as a masked, two center, randomized, placebo-controlled pilot study to evaluate the safety and efficacy of nasal and oral inhalation of 75 mg aztreonam in subjects with CF and lung infection due to PA. The study will involve two sites: Virginia Commonwealth University Medical ...
What is the current status of trial NCT02730793?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2017-01. Estimated completion is 2019-09-19.
What interventions are being tested in trial NCT02730793?
The interventions under investigation include: Nasal Placebo (DRUG), Oral Aztreonam (DRUG), Nasal Aztreonam (DRUG).
Who is sponsoring clinical trial NCT02730793?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02730793's enrollment target sits among peer trials
5 2000th of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia